Forbes January 2, 2025
For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very popular as weight loss treatments. Taken in accordance with instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a person’s weight. Given the various co-morbidities associated with obesity, including diabetes and cardiovascular disease, intuitively, it would seem that GLP-1 use for weight loss would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.
The pharmacy benefit manager Prime Therapeutics released a study in October stating that “findings indicate in the real world that individuals taking GLP-1 therapies without diabetes [over a two year period] will see...
Today's Sponsors
Today's Sponsor